159992 创新药
已收盘 04-17 15:00:00
资讯
新帖
简况
九典制药：公司正全面推进向创新药研发的战略转型
证券之星 · 04-17 20:51
九典制药：公司正全面推进向创新药研发的战略转型
从长期“烧钱”到整体盈利！沙利文：创新药企进入投资价值兑现期
21世纪经济报道 · 04-17 20:37
从长期“烧钱”到整体盈利！沙利文：创新药企进入投资价值兑现期
参照药预沟通开闸，创新药医保报价打破开“盲盒”模式
21世纪经济报道 · 04-17 18:06
参照药预沟通开闸，创新药医保报价打破开“盲盒”模式
长城基金梁福睿：关注创新药行业具备中长期价值、能真正兑现和成长的公司
市场资讯 · 04-17 17:50
长城基金梁福睿：关注创新药行业具备中长期价值、能真正兑现和成长的公司
“9号文”定价放开，创新药行情还没完
格隆汇 · 04-17 16:06
“9号文”定价放开，创新药行情还没完
4月17日昂利康（002940）涨停分析：过评提速、创新药临床驱动
证券之星 · 04-17 15:44
4月17日昂利康（002940）涨停分析：过评提速、创新药临床驱动
AI推动创新药研发效率大幅提升，关注人工智能ETF易方达（159819）等产品配置价值
证券之星 · 04-17 14:35
AI推动创新药研发效率大幅提升，关注人工智能ETF易方达（159819）等产品配置价值
破解“最凶险的乳腺癌”：为了晚期患者平均2年的生存时间延长，中国创新药做了哪些努力？| 肿瘤防治宣传周策划②
每日经济新闻 · 04-17 13:29
破解“最凶险的乳腺癌”：为了晚期患者平均2年的生存时间延长，中国创新药做了哪些努力？| 肿瘤防治宣传周策划②
创新药赛道大幅回调，港股通创新药ETF易方达（159316）半日净申购近8000万份
证券之星 · 04-17 13:14
创新药赛道大幅回调，港股通创新药ETF易方达（159316）半日净申购近8000万份
4月1日昂利康（002940）涨停分析：创新药突破、集采放量驱动
证券之星 · 04-16 15:42
4月1日昂利康（002940）涨停分析：创新药突破、集采放量驱动
中金：国家优化创新药新药上市首发价格机制 药品行业有望迎高质量发展
智通财经 · 04-16 14:24
中金：国家优化创新药新药上市首发价格机制 药品行业有望迎高质量发展
浙商证券：定价权回归市场与多元支付手段共振 创新药产业链有望迎来腾飞
智通财经 · 04-16 11:24
浙商证券：定价权回归市场与多元支付手段共振 创新药产业链有望迎来腾飞
A股药企薪酬图鉴 创新药、CXO、高端医疗器械赛道人均薪酬领先
21世纪经济报道 · 04-16 07:00
A股药企薪酬图鉴 创新药、CXO、高端医疗器械赛道人均薪酬领先
绿叶制药(02186)创新药LY03017用于治疗阿尔茨海默病精神病性障碍的中国Ⅱ期临床试验完成首例受试者入组
智通财经 · 04-15 21:03
绿叶制药(02186)创新药LY03017用于治疗阿尔茨海默病精神病性障碍的中国Ⅱ期临床试验完成首例受试者入组
创新药定价自主权松绑！14条举措健全药品价格形成机制，释放了哪些信号
澎湃新闻 · 04-15 19:49
创新药定价自主权松绑！14条举措健全药品价格形成机制，释放了哪些信号
海思科最新公告：创新药HSK47388片新增适应症获临床试验批准
证券之星 · 04-15 18:40
海思科最新公告：创新药HSK47388片新增适应症获临床试验批准
从“产品授权”到“价值共创” 科创板创新药企成全球医药创新生态重要参与者
经济参考网 · 04-15 17:11
从“产品授权”到“价值共创” 科创板创新药企成全球医药创新生态重要参与者
4月15日博瑞医药（688166）涨停分析：创新药进展、集采落地、政策加码驱动
证券之星 · 04-15 15:33
4月15日博瑞医药（688166）涨停分析：创新药进展、集采落地、政策加码驱动
国办一纸文件定调药价，创新药爆发！涨停名单还在拉长
格隆汇 · 04-15 14:33
国办一纸文件定调药价，创新药爆发！涨停名单还在拉长
创新药出海爆发！一季度BD交易额破600亿美元
每日经济新闻 · 04-15 14:26
创新药出海爆发！一季度BD交易额破600亿美元
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.848,"timestamp":1776409386000,"preClose":0.868,"halted":0,"volume":1123105151,"delay":0,"changeRate":-0.023,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.02,"latestTime":"04-17 15:00:00","open":0.863,"high":0.863,"low":0.841,"amount":954000000,"amplitude":0.0253,"askPrice":0.848,"askSize":169345,"bidPrice":0.847,"bidSize":17387,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":5,"adr":0,"adjPreClose":0.868,"symbolType":"fund","openAndCloseTimeList":[[1776389400000,1776396600000],[1776402000000,1776409200000]],"highLimit":0.955,"lowLimit":0.781,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":-0.145692,"marketValue":0,"turnoverRate":0,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-20。","floatMarketCap":0},"requestUrl":"/m/hq/s/159992/wiki","defaultTab":"wiki","newsList":[{"id":"2628209911","title":"九典制药：公司正全面推进向创新药研发的战略转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2628209911","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628209911?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:51","pubTimestamp":1776430319,"startTime":"0","endTime":"0","summary":"谢谢九典制药回复：尊敬的投资者：您好！公司正全面推进向创新药研发的战略转型，采取“多个研发中心+多种药物形式+多种合作模式”的策略。公司在中部地区和长三角布局了双创新药研发中心，目前研发平台拥有40余名专业人员，涵盖从药物设计到临床研究的各环节，核心团队具备多个创新药临床及上市申报的成功经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700043115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","159992","06978","300705","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628094192","title":"从长期“烧钱”到整体盈利！沙利文：创新药企进入投资价值兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2628094192","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628094192?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:37","pubTimestamp":1776429420,"startTime":"0","endTime":"0","summary":"近期，28家科创板创新药公司集中披露2025年度业绩快报。数据显示，28家公司合计实现营业收入约740亿元，同比增长近30%，创历史新高；归母净利润约16亿元，成功扭转亏损局面，实现了从长期“烧钱”到整体盈利的历史性跨越。约八成公司营收同比增长，六成公司利润端有所好转，百济神州、诺诚健华等多家企业首次实现扭亏为盈，预计将于2026年“摘U”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173709251397.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173709251397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628168277","title":"参照药预沟通开闸，创新药医保报价打破开“盲盒”模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2628168277","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628168277?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:06","pubTimestamp":1776420360,"startTime":"0","endTime":"0","summary":"近日，国家医保局公示第一批参照药预沟通药品信息，共31个1类创新药，涵盖肿瘤、代谢、自身免疫等领域，涉及恒瑞、信达、亚盛、罗氏、诺华等中外头部药企。从上市情况看，23个为五年内新上市药品，1个为五年内适应症或功能主治发生重大变化的药品，另外7个则为尚未获批上市药品。在业内看来，这是为新一轮医保目录调整做铺垫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173709067641.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173709067641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628277851","title":"长城基金梁福睿：关注创新药行业具备中长期价值、能真正兑现和成长的公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2628277851","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628277851?lang=zh_cn&edition=full","pubTime":"2026-04-17 17:50","pubTimestamp":1776419400,"startTime":"0","endTime":"0","summary":"近期，国内创新药及创新药产业链持续获得政策强力支持，叠加产业基本面改善与国际化突破，市场普遍看好其长期发展前景。国家药监局3月28日发布的信息显示，今年第一季度，我国创新药对外授权交易额超过600亿美元，接近2025年全年的一半。截至3月27日，今年我国已有10款创新药获批上市，其中2款为进口，8款为国产，创新药取得历史性突破。长城医药产业精选基金经理梁福睿近期就这些问题接受媒体采访，进行了专业剖析。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-04-17/doc-inhuveqy6398552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628276176","title":"“9号文”定价放开，创新药行情还没完","url":"https://stock-news.laohu8.com/highlight/detail?id=2628276176","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628276176?lang=zh_cn&edition=full","pubTime":"2026-04-17 16:06","pubTimestamp":1776413165,"startTime":"0","endTime":"0","summary":"创新药定价权回归市场","market":"us","thumbnail":"https://img3.gelonghui.com/c5097-aba8d577-67d2-44e6-ad65-3b7bda98b32d.jpg?guru_height=853&guru_width=1280&guru_size=168815","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/c5097-aba8d577-67d2-44e6-ad65-3b7bda98b32d.jpg?guru_height=853&guru_width=1280&guru_size=168815"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4456660","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159992","BK1161","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628276898","title":"4月17日昂利康（002940）涨停分析：过评提速、创新药临床驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2628276898","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628276898?lang=zh_cn&edition=full","pubTime":"2026-04-17 15:44","pubTimestamp":1776411875,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康4月17日涨停收盘，收盘价39.16元。该股于10点17分涨停，1次打开涨停，截止收盘封单资金为6392.48万元，占其流通市值0.88%。今日昂利康涨停的可能因素有：公司于2026年4月15日公告盐酸阿罗洛尔片通过一致性评价，为国内第二家获批企业；同期披露子公司创新药AL-001获CDE默示许可进入I期临床；叠加近期医药板块政策面回暖，创新药与仿制药双轮驱动逻辑受市场关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700025764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239","06978","BK1161","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628944278","title":"AI推动创新药研发效率大幅提升，关注人工智能ETF易方达（159819）等产品配置价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2628944278","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628944278?lang=zh_cn&edition=full","pubTime":"2026-04-17 14:35","pubTimestamp":1776407757,"startTime":"0","endTime":"0","summary":"长期来看，AI与创新药的深度融合将显著降低创新药的试错成本，驱动生命科学从“经验驱动”转向“精准计算”，推动AI制药行业进入黄金时代。中证人工智能主题指数全面覆盖AI产业链上中下游核心环节，恒生港股通创新药指数成份股不含CXO公司，100%聚焦创新药企。人工智能ETF易方达、港股通创新药ETF易方达分别跟踪以上指数，管理费率均为0.15%/年，可助力投资者把握AI制药融合趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026041700022964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","06978","BK1161","BK1574","159819"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628227488","title":"破解“最凶险的乳腺癌”：为了晚期患者平均2年的生存时间延长，中国创新药做了哪些努力？| 肿瘤防治宣传周策划②","url":"https://stock-news.laohu8.com/highlight/detail?id=2628227488","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628227488?lang=zh_cn&edition=full","pubTime":"2026-04-17 13:29","pubTimestamp":1776403740,"startTime":"0","endTime":"0","summary":"青青（化名）坐在湖南省肿瘤医院的诊室里等待检查结果。此时距离她入组三阴性乳腺癌的一项III期临床试验已经一年有余，她的语气里带着一种劫后余生的庆幸：“医生说，我是疗效最好的受试者之一。”三年前，当“三阴性乳腺癌”这六个字从天而降时，她的世界曾经轰然坍塌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173708745959.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173708745959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628122206","title":"创新药赛道大幅回调，港股通创新药ETF易方达（159316）半日净申购近8000万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2628122206","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628122206?lang=zh_cn&edition=full","pubTime":"2026-04-17 13:14","pubTimestamp":1776402893,"startTime":"0","endTime":"0","summary":"4月17日早盘，市场低位震荡，创新药赛道大幅回调，指数层面，恒生港股通创新药指数下跌2.4%，中证创新药产业指数下跌2.9%，港股通创新药ETF易方达半日净申购近8000万份。港股通创新药ETF易方达跟踪的恒生港股通创新药指数在编制方案中明确剔除CXO公司，100%聚焦创新药核心企业，Wind数据显示，该产品管理费率为同类中最低一档的0.15%/年，可助力投资者低成本把握创新药商业化提速机遇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026041700022579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","BK1574","BK1161","159316"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627267717","title":"4月1日昂利康（002940）涨停分析：创新药突破、集采放量驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2627267717","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627267717?lang=zh_cn&edition=full","pubTime":"2026-04-16 15:42","pubTimestamp":1776325362,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康4月16日涨停收盘，收盘价35.6元。今日昂利康涨停的可能因素有：定增方案修订拟募资11.2亿元加码创新药研发，重点推进ALK-N001 I期临床；年内获头孢克肟等6个药品证书及3个视同过评批件；12个产品拟中选国家集采；子公司获批“吸入用七氟烷（宠物用）”兽药批件，正式切入千亿级宠物药赛道；2025年净利预增36.93%-71.78%，年报预增兑现；叠加创新药+原料药+集采+宠物药多重概念共振。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600023603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK1574","BK1161","06978","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627261720","title":"中金：国家优化创新药新药上市首发价格机制 药品行业有望迎高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2627261720","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627261720?lang=zh_cn&edition=full","pubTime":"2026-04-16 14:24","pubTimestamp":1776320685,"startTime":"0","endTime":"0","summary":"中金主要观点如下：优化创新药等新上市药品首发价格机制，实行新上市药品企业自评制度政策鼓励对于新上市药品价格制定，区分高水平创新药、改良新药、通用名药等情形。根据真实世界研究结果和临床使用实效，医药企业可在药品首发价格基础上适当调整价格水平。促进创新药多元支付与价格合理形成，拓宽创新药支付渠道。风险因素研发不及预期，创新药核心产品对外合作进展不及预期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023057109.AUD","LU2097828805.USD","LU0348827113.USD","LU0417516738.SGD","LU1770034418.SGD","LU2476274308.USD","09606","LU1961090484.USD","159992","09926","HK0000252160.HKD","HK0000500386.USD","LU1719994722.HKD","06160","LU0455707207.USD","LU0348766576.USD","LU2476274720.SGD","BK1588","LU0348784397.USD","LU2399975544.HKD","LU0634319403.HKD","LU0540923850.HKD","LU0348825331.USD","LU0348783233.USD","06990","LU0359202008.SGD","LU0417516902.SGD","IE00B543WZ88.USD","LU1794554557.SGD","06978","LU2097828714.EUR","LU2328871848.SGD","BK1161","LU0196878994.USD","LU0502904849.HKD","LU0307460666.USD","BK1191","LU0561508036.HKD","LU0417516571.SGD","IE00B5MMRT66.SGD","IPOS","LU2097828631.EUR","LU0588546209.SGD","LU2543165471.USD","LU2778985437.USD","HK0000165453.HKD","01276","LU2097828557.USD","01801","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627268256","title":"浙商证券：定价权回归市场与多元支付手段共振 创新药产业链有望迎来腾飞","url":"https://stock-news.laohu8.com/highlight/detail?id=2627268256","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627268256?lang=zh_cn&edition=full","pubTime":"2026-04-16 11:24","pubTimestamp":1776309848,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，浙商证券发布研报称，《关于健全药品价格形成机制的若干意见》的出台有望极大拉高国内创新药商业化放量的天花板。该行认为国内创新药销售峰值预期将会得到提升，极大调动企业的积极性，整个行业由以往的出海驱动演变为国内、海外双轮驱动，行业的景气度和确定性进一步增强。一方面将使得内需型药品创新产业链各环节的盈利空间得到优化，另一方面将进一步提振国内创新药研发需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601878","BK1161","06978","159992","BK1574","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627325669","title":"A股药企薪酬图鉴 创新药、CXO、高端医疗器械赛道人均薪酬领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2627325669","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627325669?lang=zh_cn&edition=full","pubTime":"2026-04-16 07:00","pubTimestamp":1776294000,"startTime":"0","endTime":"0","summary":"随着A股年报相继出炉，各企业年薪再次成为焦点。截至2026年4月初，A股已有130家医药生物上市公司完整披露2025年人均薪酬数据。同花顺问财数据显示，医药行业内部薪酬分化极为显著，创新药、CXO、高端医疗器械三大赛道凭借高研发投入与技术壁垒，人均薪酬遥遥领先；而传统仿制药、中药、医药流通等领域则深陷薪酬洼地，行业最高与最低企业年薪差距超8倍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhurtwq7427621.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhurtwq7427621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","BK1583","159883","09997","399300","BK1222","06978","BK1574","159982","159992","BK1161","BK1100","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627335287","title":"绿叶制药(02186)创新药LY03017用于治疗阿尔茨海默病精神病性障碍的中国Ⅱ期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2627335287","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627335287?lang=zh_cn&edition=full","pubTime":"2026-04-15 21:03","pubTimestamp":1776258221,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药 发布公告，集团自主研发的创新药LY03017用于治疗阿尔茨海默病精神病性障碍的中国Ⅱ期临床试验已完成首例受试者入组。此次开展的中国Ⅱ期临床试验为一项随机、双盲、平行、安慰剂对照研究，旨在评估LY03017治疗阿尔茨海默病精神病性障碍相关幻觉和妄想的初步疗效和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02186","BK1161","BK1606","BK1583","BK1574","06978","159992","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627428132","title":"创新药定价自主权松绑！14条举措健全药品价格形成机制，释放了哪些信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2627428132","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627428132?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:49","pubTimestamp":1776253740,"startTime":"0","endTime":"0","summary":"4月15日，创新药板块走高。 消息面上，4月14日，国务院办公厅发布《关于健全药品价格形成机制的若干意见》。《意见》提出14条举措，包括优化创新药等新上市药品首发价格机制、发挥医保支付标准对药品价格形成的引导作用、引导药店合理制定药品零售价格、强化短缺药保供稳价等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-04-15/doc-inhuqsma7887286.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-15/doc-inhuqsma7887286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627285939","title":"海思科最新公告：创新药HSK47388片新增适应症获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2627285939","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627285939?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:40","pubTimestamp":1776249612,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)公告称，公司近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，同意公司自主研发的创新药HSK47388片(I)开展新增适应症的临床试验。该新增适应症为炎症性肠病，包括溃疡性结肠炎和克罗恩病。HSK47388片(I)属于化学药品1类，是一款口服、强效、高选择性药物。目前，该药品的银屑病适应症正处于Ⅱ期临床阶段。临床前研究显示，该药在肠炎模型中呈现显著药效，有望为消化系统疾病患者提供新的治疗选择。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500035632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK0028","BK1574","BK0077","BK0033","BK0188","002653","BK1161","06978","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627071344","title":"从“产品授权”到“价值共创” 科创板创新药企成全球医药创新生态重要参与者","url":"https://stock-news.laohu8.com/highlight/detail?id=2627071344","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627071344?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:11","pubTimestamp":1776244286,"startTime":"0","endTime":"0","summary":"近期，科创板生物医药企业进入年报密集披露期。4月14日，百济神州2025年年报显示，公司实现业绩稳健增长并扭亏为盈，即将摘“U”出层。这份“十四五”收官的成绩单，不仅展现了创新药企的成果兑现能力，更揭开了科创板医药企业面向“十五五”的全球化新布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705999237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","06978","BK1515","BK1574","159982","159992","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627409734","title":"4月15日博瑞医药（688166）涨停分析：创新药进展、集采落地、政策加码驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2627409734","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627409734?lang=zh_cn&edition=full","pubTime":"2026-04-15 15:33","pubTimestamp":1776238408,"startTime":"0","endTime":"0","summary":"证券之星消息，博瑞医药4月15日涨停收盘，收盘价57.66元。该股于11点22分涨停，1次打开涨停，截止收盘封单资金为1.21亿元，占其流通市值0.49%。今日博瑞医药涨停的可能因素有：BGM0504注射液国内III期临床完成入组、美国II期会议顺利结束，与华润三九达成商业化合作；地诺孕素片及布地奈德混悬液获批，4个产品拟中标国家集采接续采购；工信部吹风加快打造“创新医药”，明确支持创新药加速上市与合理定价，政策催化显著。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500022614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1574","688166","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405121","title":"国办一纸文件定调药价，创新药爆发！涨停名单还在拉长","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405121","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405121?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:33","pubTimestamp":1776234822,"startTime":"0","endTime":"0","summary":"政策组合拳出击","market":"sh","thumbnail":"https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4422353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","BK1587","002589","BK0096","000919","BK0132","BK0185","BK0239","600488","000788","BK1583","BK0122","BK0209","BK0250","159992","BK0012","06990","BK0060","600572","BK0102","BK0188","BK0077","600267","BK1574","BK0070","BK0097","BK0028","02162","06978","002038","301408","LU0196878994.USD","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405527","title":"创新药出海爆发！一季度BD交易额破600亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405527","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405527?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:26","pubTimestamp":1776234405,"startTime":"0","endTime":"0","summary":"今日，医药板块持续走强，恒生生物科技指数（HSBIO.HI）盘中涨幅3.21%。相关ETF方面，港股通生物科技ETF（159102）场内价格现涨2.91%。截至上个交易日数据，该基金15日累计涨幅8.26%，动能强劲。成分股方面，三生制药涨超6%，康方生物涨超4%，信达生物涨超3%，映恩生物-B、科伦博泰生物-B、晶态控股等涨幅靠前。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705806464.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705806464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159992","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776490221364,"stockEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":0.0443},{"period":"3month","weight":-0.0385},{"period":"6month","weight":-0.0567},{"period":"1year","weight":0.1977},{"period":"ytd","weight":0.0205}],"compareEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":-0.0028},{"period":"3month","weight":-0.0123},{"period":"6month","weight":0.0551},{"period":"1year","weight":0.2351},{"period":"ytd","weight":0.0208}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}